NEW YORK (GenomeWeb News) – Biopharmaceutical firm Amgen is acquiring genomic research products firm Decode Genetics for $415 million, the companies announced today.

The all-cash deal has been approved by Amgen's board and is expected to be completed before the end of the year.

In a statement Amgen President and CEO Robert Bradway said the deal "fits perfectly" with the company's goal of pursuing the rapid development of relevant molecules for disease targets without wasting money on targets that aren't as well validated.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.